CORDIS
EU research results

CORDIS

English EN

Molecular mechanisms of neuronal restoration: novel approaches for Parkinson's Disease

Objective

MOLPARK aims to define the basic cellular and molecular mechanisms underlying the generation, differentiation, survival and connectivity of nigrostriatal dopaminergic neurons and translate this knowledge into radically new therapeutic strategies for Parkinson's disease (PD). MOLPARK brings together two industrial partners and 6 world-renowned academic groups with a uniquely advantageous knowledge platform based on complementary state-of-the-art technologies and recent relevant discoveries in their laboratories. These include, unique approaches for stem cell renewal control based on novel insights into the function of GABA receptors and intracellular signaling components such as Bex1, novel neurotrophic factors for dopaminergic neurons such as CDNF and MANF, novel approaches to harness the power of GDNF and Wnt proteins for stimulating the growth of dopaminergic terminals and novel ways to enhance synaptogenesis, MOLPARK’s strategy is based on four major interrelated objectives. I). Define the mechanisms of stem cell self-renewal, differentiation and integration and exploit these mechanisms to induce or boost existing self-repair processes with the aim of replenishing neurons in PD. 2). Define the mechanisms for sustaining dopaminergic neuron survival in health and disease with the aim of developing new, effective growth factor-based therapies aimed at protecting neurons in PD. 3). Define the mechanisms that promote the growth of DA nigrostriatal axons and dendrites with the aim of identifying therapeutic strategies based on restoring neural processes in PD. 4). Define the mechanisms that promote and sustain the synaptic connections of dopaminergic neurons with the aim of restoring connections in PD.

Coordinator

CARDIFF UNIVERSITY

Address

Newport Road 30-36
Cf24 Ode Cardiff

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 636 163

Administrative Contact

Nick Bodycombe (Mr.)

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 1 035 517

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 388 162

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 388 162

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 517 760

ACTAR AB

Sweden

EU Contribution

€ 253 444

CHARLES RIVER DISCOVERY RESEARCH SERVICES FINLAND OY

Finland

EU Contribution

€ 253 445

Project information

Grant agreement ID: 223489

Status

Closed project

  • Start date

    1 April 2009

  • End date

    30 September 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 590 740,40

  • EU contribution

    € 3 472 653

Coordinated by:

CARDIFF UNIVERSITY

United Kingdom